Creative Capital Management Investments’s BridgeBio Pharma BBIO Stock Holding History

Creative Capital Management Investments’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.08K	Buy	+28	New	+$1.96K	﹤0.01%	783

Other funds holding BBIO

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Creative Capital Management Investments's BBIO Position: Q2 2026 in Review

Creative Capital Management Investments opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 28 shares worth $2.08K. The stake represents ﹤0.01% of the portfolio and ranks #783 among its holdings.

73 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Creative Capital Management Investments held 28 shares of BridgeBio Pharma worth $2.08K as of Q2 2026.
BridgeBio Pharma was a new Creative Capital Management Investments position in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #783 holding.
73 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.